250. Tigecycline Susceptibility Trends among Pathogens Isolated from Complicated Skin and Soft Tissue Infections in North and Latin America: 2012-2016
Session: Poster Abstract Session: Clinical: Skin and Soft Tissue
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • Pfizer_P84_Tigecycline Skin Soft Tissue NA LA_IDSA 2017_Final.pdf (499.0 kB)
  • Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of tigecycline and other antimicrobials against clinically-relevant pathogens collected globally. This study reports the activity of tigecycline (TGC) against gram-positive and gram-negative isolates collected in North and Latin America from patients with complicated skin and soft tissue infections (CSSTI).

    Methods: Hospital sites from North America (NA) and Latin America (LA) collected non-duplicate clinical gram-positive and -negative isolates from various complicated skin and skin structure infection sources during 2012-2016. Organism identification and antibiotic susceptibility (S) testing was performed by the local laboratories. Susceptibility testing was determined using the broth microdilution method according to CLSI guidelines and categorical interpretation of results was done using CLSI or FDA (tigecycline) breakpoint criteria where appropriate. Cefoxitin disk testing was performed for all S. aureus to determine methicillin susceptibility (i.e. MRSA and MSSA).

    Results:

    The table provides %S and MIC90 data for TGC against CSSTI isolates

    Region, n, %S, MIC90 (µg/ml)

    North America

     

    Latin America

     

    Organism

    n

    %S

    MIC90

    n

    %S

    MIC90

    S. aureus

    2270

    100

    0.12

    310

    100

    0.25

    Enterobacter spp.

    925

    96.4

    1

    159

    92.5

    2

    P. aeruginosa

    758

    na*

    > 8

    165

    na

    > 8

    E. coli

    716

    99.9

    0.25

    241

    100

    0.25

    Enterococcus spp.

    691

    99.3

    0.12

    135

    100

    0.12

    S. agalactiae

    503

    100

    0.12

    58

    100

    0.06

    K. pneumoniae

    471

    94.9

    2

    152

    91.5

    2

    S. marcescens

    347

    96.8

    2

    67

    97.0

    2

    A. baumannii

    310

    na*

    2

    97

    na

    1

    K. oxytoca

    204

    99.0

    0.5

    15

    100

    1

    *na = not applicable or no breakpoints available for this species

    Conclusion: Based on %S and MIC90 data TGC exhibited potent activity against isolates of all organism groups from complicated skin and soft tissue infections, regardless of the geographic region. However, given the potential many of these organisms have for developing resistance, continued and careful surveillance monitoring is warranted.

    Daryl Hoban, PhD1, Martha Renteria, MD2, Heidi Leister-Tebbe, BSN3 and Dan Sahm, PhD2, (1)IHMA, Inc., Schaumburg, IL, (2)International Health Management Associates, Inc., Schaumburg, IL, (3)Pfizer, Inc., Collegeville, PA

    Disclosures:

    D. Hoban, None

    M. Renteria, IHMA, Inc: Employee , Salary

    H. Leister-Tebbe, Pfizer: Employee , Salary

    D. Sahm, None

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.